1. Home
  2. PRMB vs KNSA Comparison

PRMB vs KNSA Comparison

Compare PRMB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primo Brands Corporation

PRMB

Primo Brands Corporation

N/A

Current Price

$23.33

Market Cap

8.0B

Sector

N/A

ML Signal

N/A

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

N/A

Current Price

$93.77

Market Cap

7.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRMB
KNSA
Founded
1955
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.7B
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
PRMB
KNSA
Price
$23.33
$93.77
Analyst Decision
Buy
Strong Buy
Analyst Count
12
7
Target Price
$28.36
★ $111.57
AVG Volume (30 Days)
★ 5.6M
800.1K
Earning Date
11-05-2026
10-27-2026
Dividend Yield
★ 2.06%
N/A
EPS Growth
★ 328.57
225.00
EPS
0.60
★ 1.14
Revenue
★ $6,664,000,000.00
$677,564,000.00
Revenue This Year
$2.65
$54.80
Revenue Next Year
$3.45
$28.50
P/E Ratio
★ $38.78
$82.02
Revenue Growth
29.34
★ 60.09
52 Week Low
$14.80
$37.02
52 Week High
$26.21
$99.31

Technical Indicators

Market Signals
Indicator
PRMB
KNSA
Relative Strength Index (RSI) 63.01 55.90
Support Level $23.42 $87.30
Resistance Level $23.78 $98.90
Average True Range (ATR) 0.89 4.01
MACD 0.12 -0.45
Stochastic Oscillator 72.32 54.29

Price Performance

Historical Comparison
PRMB
KNSA

About PRMB Primo Brands Corporation

Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: